Author: Ken Dropiewski

Silk Road Medical Announces Key TCAR Presentations at 2018 VEITHsymposium

SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced that multiple podium presentations at the upcoming VEITHsymposium Nov. 13-17 at the New York Hilton-Midtown will feature the company’s TransCarotid Artery Revascularization (TCAR) procedure. One-year results from the Society […]

BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the […]

InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones

SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today provided a corporate update highlighting fundraising and clinical development milestones.  These achievements have contributed to the continued successful development of its lead clinical program, while […]

Amarin to Present at the Jefferies 2018 London Healthcare Conference

BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 08, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a general company update at […]

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)

NEW HOPE, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that Professor Petr Neuzil, M.D., Head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech […]

CHF Solutions to Release Educational Webinar Highlighting Use of Aquadex FlexFlow® System in Post-Cardiovascular Surgery Featuring Noted Cardiovascular Surgeon, Daniel Beckles, MD, PhD

EDEN PRAIRIE, Minn., Nov. 08, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS), today announced that it will release an educational webinar featuring the clinical use of the Aquadex FlexFlow system following cardiovascular surgery in patients who have failed diuretic therapy.  The webinar will be viewable on the company’s […]

MEDTRONIC BEGINS RENAL DENERVATION STUDY FOR HIGH BLOOD PRESSURE PATIENTS PRESCRIBED ANTI-HYPERTENSIVE MEDICATION

DUBLIN – November 8, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications. The SPYRAL HTN-ON MED Trial is the […]

MyoKardia Reports Third Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018. “MyoKardia continues to make encouraging progress toward our mission of changing the […]